Friday, March 24th, 2023

The soft tissue sarcoma market

Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance       


Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.


Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified.


To order this 130+ slides report, which features 80+ figures, please visit


Key Market Insights


70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma

Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma.


Around 65% of the therapeutics are being developed as small molecules

Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment.


More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market

North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders.


Around 75 eminent scientists were identified as key opinion leaders (KOLs)

65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities.


North America is anticipated to capture over 70% of the global market share in 2030

In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030.


To request a sample copy / brochure of this report, please visit this


Key Questions Answered

  • Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?
  • Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?
  • Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?
  • Which companies are actively involved in conducting clinical trials for their therapeutic candidates?
  • Which partnership models are most commonly adopted by stakeholders in this industry?
  • What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?
  • Who are the prominent KOLs evaluating therapies within this industry?


For additional details, please visit mailto:or email

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at


Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

Leave a Reply

Your email address will not be published. Required fields are marked *